We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


EKF Molecular to Exhibit at AMP 2014

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "EKF Molecular to Exhibit at AMP 2014"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

EKF Diagnostics has announced that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology (AMP) annual meeting on booth 1028, to discuss with delegates the predicted outcomes of its research collaboration with Massachusetts General Hospital (MGH).

Under the two year agreement, EKF Molecular will develop high sensitivity assays for the detection of genetic variation in circulating tumour cells (CTCs), using its PointMan™ DNA enrichment technology. MGH will clinically validate PointMan in lung, breast and skin cancer, using CTCs isolated from a patient’s blood by MGH’s CTC-Chip instrument.

Andrew Webb, CEO of EKF Molecular Diagnostics Ltd, commented: “This new work follows the initial pilot studies conducted by MGH which suggested that PointMan can detect three mutant alleles in a background of 30,000 wild-type alleles, isolated from CTCs and circulating cell-free DNA. My colleagues Gary Dowthwaite, Product Manager, and Victoria Wilson, Business Development Manager and I are looking forward to discussing the potential opportunities to improve the clinical management of patients, offered by this further collaboration with MGH”.